patients with most active inflammation who have a higher risk of relapses/recurrences [1]. This is the first application of PDUS to PMR but some aspects should be discussed.
PMR lesions was used to justify the significant lower subacromial-subdeltoid (SA-SD) bursitis frequency (ranging from 16 to 70%) reported in previous US studies [3] [4] [5] [6] , with respect to their observations (frequency ranging from 96 to 100%) [2, 7] . In fact, the authors proposed to explain the lower frequencies of SA-SD bursitis in these previous PMR series with the probable use of corticosteroids before US examination.
The US persistence of SA-SD bursitis despite corticosteroid treatment gives a new validity to the results of these previous series and this could reopen the debate on the real frequency of SA-SD bursitis in PMR at onset and, consequently, on the real accuracy of this finding for the diagnosis of PMR.
In a recent work of our group (data not published) we confirm a 79% frequency of SA-SD bursitis in PMR at onset, lower than was observed by Salvarani's group [2, 7] . Our result supports that SA-SD bursitis is a cardinal feature of PMR, but with moderate accuracy to differentiate at-onset PMR patients from patients with chronic arthritides of other nature. We also proposed to use US and PDUS to make a multi-district screening in order to obtain more findings, possibly indicating other diagnosis than PMR (active synovitis of wrist, MCP and MTP joints for elderly onset RA, enthesitis for elderly onset SpA, menisci and tendon calcifications for crystal-related arthritides).
The surprising persistence of inflammatory findings in PMR shoulders (59% of patients in remission or with low disease activity) also with positive PD signals, after a mean of 24 weeks with prednisone therapy seems a strong indicator for chronic synovitis, and a diagnosis of chronic arthritis should be considered. An analysis of SF should be useful in these situations, to also exclude crystal-related arthritis, which is reported as a condition frequently mimicking PMR [8] .
Moreover, protracted active shoulder synovitis (with PD signals) unresponsive to corticosteroids, could induce secondary joint changes such as juxta-articular osteoporosis, capsular and ligamentous degeneration with joint instability, regardless of diagnosis. In our opinion, this situation should induce clinicians to introduce DMARDs to prevent disease progression and joint damage. [2] . Their observations are relevant and some explanation is needed in response.
Our previous longitudinal study [3] on PMR patients cited by Falsetti et al. is an MRI study conducted in a small group of patients after repeated shoulder bilateral injection of CSs, so its results are not directly comparable with those obtained in this study on patients treated with continuous oral CS and studied with ultrasonography (US) and Power Doppler Ultrasonography (PDUS). It is conceivable that local high-dose (40 mg of 6-methylprednisolone acetate) CS injection will have faster results than low oral CS treatment.
Their considerations about the real frequency of subacromial-subdeltoid (SA-SAD) bursitis and its role as diagnostic criteria for PMR was not an objective of our study and we think will be answered by an european league against rheumatism and ACR longitudinal multicentre study, the results of which will be presented soon. Differences in the selection of PMR patients and in the definition of US pathological inflammatory conditions, and the diverse probes and US machines utilized in the different studies may explain the wide range of reported prevalence in the literature of inflammation in articular and periarticular structures in PMR patients.
The persistence of US signs of inflammation even after 6 months of CS treatment is not that surprising and there are some explanations, as follows.
The sensitivity of US and PDUS in identifying signs of inflammation is significantly superior when compared with that of clinical examination. In rheumatological conditions, many studies have demonstrated that US and PDUS can identify inflammation in patients in clinical remission or in asymptomatic areas at enthesis or at joint level [4] [5] [6] [7] . In our study we have demonstrated that also in PMR the increased sensitivity of US can identify patients with persistant US signs of disease activity but in clinical remission. Of the group of patients who entered our study, five still have signs of US shoulder periarticular inflammation after a mean follow-up of 26 months and three are CS free in persistent remission.
There is the possibility that some of our patients were incorrectly classified as PMR and that the persistence of signs of inflammation may have been related to the presence of a different inflammatory rheumatological condition. We know that a small percentage of patients diagnosed as PMR develop clinical findings of RA or other inflammatory articular conditions and that sometimes it is difficult to differentiate these syndromes at onset and only the patient follow-up will clarify the definitive diagnosis [8] . In the group of patients enrolled in our study, 12 had signs and symptoms of peripheral joint involvement at onset and 35% had US signs of gleno-humeral (GH) synovitis (mono or bilateral). At the time of the second examination after CS treatment, none had signs of peripheral arthritis and only one had persistent US signs of GH synovitis with Power Doppler signal. This patient was persistently RF negative and anti-cyclic citrullinated peptide negative, never developed peripheral erosions at follow-up and is now in complete clinical remission without treatment. Therefore, we are confident that PMR diagnosis in this particular patient was correct. 
